NCT03889600 is a NA clinical trial of REDD-CAT in Diabetes Mellitus, Type 2, sponsored by Boston Medical Center.

Who is sponsoring NCT03889600?

NCT03889600 is sponsored by Boston Medical Center.

What drugs are being tested in NCT03889600?

Interventions in NCT03889600: REDD-CAT.

What condition does NCT03889600 study?

NCT03889600 studies Diabetes Mellitus, Type 2.

Is NCT03889600 still recruiting?

NCT03889600 is currently withdrawn. Last updated 6 March 2023.

Last reviewed 2023-03-06 · How we verify

NCT03889600

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Re-Engineered Discharge for Diabetes-Computer Adaptive Testing (REDD-CAT)

Withdrawn NA Last updated 6 March 2023

What this trial tests

NA trial testing REDD-CAT in Diabetes Mellitus, Type 2. Withdrawn.

Timeline

2 March 2021

Primary endpoint
13 April 2021

13 April 2021

Quick facts

Lead sponsor	Boston Medical Center
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Start date	2 March 2021
Primary completion	13 April 2021
Estimated completion	13 April 2021
Sites	1 location across United States

Drugs / interventions tested

REDD-CAT

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Boston Medical Center

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Over 27 million Americans are diagnosed with Type 2 Diabetes Mellitus (T2DM), and their health outcomes, including hospitalization, emergency department use, and hospital readmission, are largely driven by social determinants; diabetes complications are largely attributable to unmet health-related social needs. Investigators will conduct a pilot feasibility trial of the Re-Engineered Discharge for Diabetes-Computer Adaptive Testing (REDD-CAT) system to inform the design of a future, fully-powered randomized controlled trial. REDD-CAT will allow clinical staff to preemptively link patients with community-based social services tailored to meet their unique needs in order to reduce avoidable hospitalization and emergency department visits.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Boston Medical Center trials

Trials by the same sponsor.

NCT06679114 — Preventing Mental Disorders Among Women Internally Displaced by War in Ukraine: The SHAWL Trial · NA · completed
NCT06093893 — Hypotensive Anesthesia for Orthognathic Surgery · Phase 4 · completed
NCT06489522 — Parenting Intervention for Mothers With Substance Use Disorder · NA · completed
NCT05769218 — PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study · NA · recruiting
NCT06427967 — A Novel Social Emotional Learning Curriculum for Youth With Epilepsy · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03889600 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boston Medical Center
Last refreshed: 6 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03889600.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing